0
Signin
countryflagUS

18889881171

AAPL 169.02 1.2702% MSFT 409.06 0.3656% GOOG 161.1 0.7379% GOOGL 159.13 0.5497% AMZN 176.59 -1.6431% NVDA 796.77 -3.3316% META 493.5 -0.5241% TSLA 162.13 12.0611% TSM 132.97 -0.3448% LLY 732.2 -1.8091% V 275.02 0.332% AVGO 1256.82 0.6108% JPM 193.08 0.4892% UNH 487.3 0.2304% NVO 126.16 -1.9279% WMT 59.87 1.32% LVMUY 171.62 -0.1106% XOM 121.05 0.0165% LVMHF 859.75 -0.3073% MA 462.5 -0.0691%

Royalty Pharma Plc

Healthcare US RPRX

27.98USD
0.16(0.58%)

Last update at 2024-04-24T20:00:00Z

Day Range

27.6028.00
LowHigh

52 Week Range

25.7338.94
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 230.06M 1241.20M 1702.00M 2461.42M 1517.86M
Minority interest 187.23M 621.47M 726.91M 35.88M 63.87M
Net income 42.83M 478.75M 555.00M 2348.53M 1377.73M
Selling general administrative 227.30M 182.83M 182.00M 103.44M 61.91M
Selling and marketing expenses - - - - -
Gross profit 2231.55M 2266.47M 2033.89M 1814.25M 1658.93M
Reconciled depreciation 5.67M 23.00M 23.06M 23.92M 33.27M
Ebit 977.50M 1430.71M 1595.00M 2623.18M 1380.35M
Ebitda 983.17M 1482.08M 1882.00M 2637.30M 1413.61M
Depreciation and amortization 5.67M 51.36M 287.00M 14.13M 33.27M
Non operating income net other 110.96M -23.37200M 263.61M - -
Operating income 977.50M 1430.71M 1595.00M 2623.18M 1364.45M
Other operating expenses 1314.32M 858.75M 527.00M -808.92200M 430.45M
Interest expense 187.96M 166.14M 157.00M 268.57M 279.96M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 78.33M 53.53M 28.38M 22.33M 24.44M
Net interest income -109.62600M -112.60700M -157.00000M -246.24400M -255.51500M
Extraordinary items - - - - -
Non recurring 1520.07M - - - -
Other items - - - - -
Income tax expense 187.23M 762.45M 1147.00M 349.33M 433.37M
Total revenue 2237.22M 2289.46M 2122.00M 1814.25M 1794.89M
Total operating expenses 1314.32M 858.75M 527.00M -808.92200M 430.45M
Cost of revenue 5.67M 23.00M 88.11M - 135.96M
Total other income expense net -747.43500M -189.51400M 107.00M -161.75700M 408.92M
Discontinued operations - - - - -
Net income from continuing ops 230.06M 1241.20M 1689.08M 2461.42M 1517.86M
Net income applicable to common shares 42.83M 619.73M 975.04M 2348.53M 1377.73M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 16813.47M 17515.87M 21097.04M 12449.90M 11370.15M
Intangible assets - 5.67M 28.67M 51.72M 75.65M
Earning assets - - - - -
Other current assets 90.52M 6.63M 8.60M 0.09M 4.70M
Total liab 7288.09M 7267.32M 6124.00M 6308.46M 6818.07M
Total stockholder equity 5628.15M 5776.59M 9896.00M 6105.56M 4488.21M
Deferred long term liab - - - - -
Other current liab 161.37M 165.63M 297.11M 9.21M 294.26M
Common stock 0.11M 0.11M 0.10M 3282.52M 3282.52M
Capital stock 0.11M 0.11M 0.10M 3282.52M 3282.52M
Retained earnings 1964.69M 2255.18M 1920.63M 2825.21M 1215.95M
Other liab 2.50M - - - -
Good will - - - - -
Other assets 13508.24M 13722.39M 5076.75M 10930.00M 8377.23M
Cash 1710.75M 1541.05M 1009.00M 283.68M 1924.21M
Cash and equivalents - - - - -
Total current liabilities 1166.78M 171.25M 307.89M 333.42M 580.17M
Current deferred revenue - - - 31.04M -
Net debt 5405.57M 5555.02M 4807.58M 5954.44M 4595.12M
Short term debt 997.51M -6891.67000M 281.98M 281.98M 281.44M
Short long term debt 997.51M - - 281.98M 281.44M
Short long term debt total 7116.32M 7096.07M 5816.58M 6238.12M 6519.33M
Other stockholder equity 3663.35M 3504.82M 7940.87M -4.26600M -10.25500M
Property plant equipment - - - - -
Total current assets 2554.91M 2878.21M 2696.90M 832.07M 2608.55M
Long term investments 14116.58M 14358.04M 12972.88M 11478.15M 8666.83M
Net tangible assets 5628.15M 5770.92M 4790.11M 6053.83M 4412.57M
Short term investments 717.04M 1262.22M 983.00M 509.53M 461.82M
Net receivables 36.60M 68.31M 39.17M 38.77M 198.63M
Long term debt 6118.81M 7096.07M 5816.58M 5956.14M 6237.90M
Inventory - - 657.14M - 19.20M
Accounts payable 7.91M 5.62M 10.78M 11.18M 4.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 3897.22M 4471.95M 5077.04M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 16.49M 34.40M 2.09M -10.25500M
Additional paid in capital - - - - -
Common stock total equity 0.11M 0.11M 0.10M 3282.52M 3282.52M
Preferred stock total equity - - - - -
Retained earnings total equity 1964.69M 2255.18M 1920.63M - -
Treasury stock -2.80600M -2.71500M -2.31700M -4.26600M -
Accumulated amortization - - - - -
Non currrent assets other 29.63M 4.14M 28.60M 87.95M 19.11M
Deferred long term asset charges - - - - -
Non current assets total 14258.56M 14637.65M 13323.39M 11617.82M 8761.59M
Capital lease obligations - - - - -
Long term debt total 6118.81M 7096.07M 5816.58M 5956.14M 6237.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1152.79400M -1832.50300M -3094.16000M -2116.14200M 573.02M
Change to liabilities 2.29M -4.58600M -0.76600M 6.50M 1.35M
Total cashflows from investing activities -1029.42100M -1870.28000M -2759.32000M -2153.62500M 303.42M
Net borrowings -1.34700M 1259.49M 728.12M -294.00000M -294.00000M
Total cash from financing activities -944.85600M 385.11M 1487.00M -1191.62600M -1379.10100M
Change to operating activities -6.08000M 8.39M 76.36M -33.63800M -11.54100M
Net income 230.06M 1241.20M 1701.95M 2461.42M 1517.86M
Change in cash 169.70M 532.37M 763.00M -1640.52900M 542.64M
Begin period cash flow 1541.05M 1008.68M 246.00M 1924.21M 1381.57M
End period cash flow 1710.75M 1541.05M 1009.00M 283.68M 1924.21M
Total cash from operating activities 2143.98M 2017.54M 2034.63M 1667.24M 1618.32M
Issuance of capital stock 0.00000M 0.00000M 1908.74M - 0.00000M
Depreciation 5.67M 23.00M 23.06M 23.92M 33.27M
Other cashflows from investing activities 123.37M -37.77700M 334.84M -258.84000M -258.84000M
Dividends paid -333.32200M -285.18400M -397.00000M -739.27600M 814.36M
Change to inventory - - - - -
Change to account receivables 2543.69M 2295.72M 162.32M 287.73M 500.40M
Sale purchase of stock -144.11500M -479.60400M 11891.00M - 0.00000M
Other cashflows from financing activities -611.53400M 670.30M -706.00000M -158.35000M -270.74200M
Change to netincome 64.12M 37.52M 50.04M -978.59400M -296.01900M
Capital expenditures 2041.15M 0.52M 2197.00M 1721.29M 269.59M
Change receivables - - - - -
Cash flows other operating 2079.86M 1980.02M 1984.59M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 169.70M 532.37M 762.48M - -
Change in working capital 32.66M -16.32200M -1884.00900M -1673.50800M -1562.37900M
Stock based compensation 2.17M 2.44M 5.43M - -
Other non cash items 1873.41M 2289.58M 2122.71M 855.40M 1629.57M
Free cash flow 4185.13M 2018.06M 4231.63M 1667.24M 1887.91M

Fundamentals

  • Previous Close 27.82
  • Market Cap16416.63M
  • Volume1749989
  • P/E Ratio70.64
  • Dividend Yield2.90%
  • EBITDA1016.68M
  • Revenue TTM2324.23M
  • Revenue Per Share TTM5.20
  • Gross Profit TTM 1332.97M
  • Diluted EPS TTM0.39

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RPRX
Royalty Pharma Plc		 0.16 0.58% 27.98 70.64 6.62 6.98 1.97 7.12 29.57
NVO
Novo Nordisk A/S		 -2.48 1.93% 126.16 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.58 1.23% 126.80 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.15 1.02% 400.76 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 -0.61 0.67% 90.10 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma Plc

110 East 59th Street, New York, NY, United States, 10022

Key Executives

Name Title Year Born
Mr. Pablo Gerardo Legorreta Founder, Chairman & CEO 1964
Mr. Terrance P. Coyne Exec. VP & CFO NA
Mr. George Wingate Lloyd Exec. VP of Investments & Chief Legal Officer 1959
Mr. Christopher Hite Vice Chairman & Exec. VP 1967
Dr. Marshall Urist M.D., Ph.D. Exec. VP and Head of Research & Investments NA
Mr. Arthur R. McGivern J.D. Exec. VP of Investments & Gen. Counsel NA
Ms. Kristin Stafford Sr. VP & Chief Accounting Officer NA
Dr. James Folmar Reddoch Ph.D. Exec. VP of Investments & Chief Scientific Officer 1970
Mr. George Grofik C.F.A., CPA Sr. VP and Head of Investor Relations & Communications NA
Ms. Alessandra Sassun VP & Head of Human Capital NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).